Dec. 14 (Bloomberg) -- Roche Holding AG’s RoActemra won the backing of the U.K.’s National Institute for Health and Clinical Excellence in final guidelines for treating patients with systemic juvenile idiopathic arthritis.
The guidelines would allow RoActemra as an option for children age 2 and older whose illness hasn’t adequately responded to other therapies, as long as Basel, Switzerland-based Roche makes the drug available to the state-run medical system at a discount, the institute, known as NICE, said today in an e-mailed statement.
NICE advises the National Health Service on the cost-effectiveness of treatments.
To contact the reporter on this story: Kristen Hallam in London at firstname.lastname@example.org
To contact the editor responsible for this story: Phil Serafino at email@example.com